labetalol has been researched along with Kidney Failure, Chronic in 13 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Three renal transplant recipients developed potentially life-threatening hyperkalemia after receiving intravenous labetalol for postoperative hypertension." | 7.68 | Hyperkalemia associated with intravenous labetalol therapy for acute hypertension in renal transplant recipients. ( Arthur, S; Greenberg, A, 1990) |
| " It has also been used intravenously in phaeochromocytoma, tetanus, clonidine withdrawal, and as an adjunct to halothane to produce hypotensive anaesthesia." | 4.76 | Combined alpha- and beta-receptor inhibition in the treatment of hypertension. ( Prichard, BN, 1984) |
| "Three renal transplant recipients developed potentially life-threatening hyperkalemia after receiving intravenous labetalol for postoperative hypertension." | 3.68 | Hyperkalemia associated with intravenous labetalol therapy for acute hypertension in renal transplant recipients. ( Arthur, S; Greenberg, A, 1990) |
| "The efficacy of labetalol in lowering blood pressure was assessed in 18 patients with chronic renal failure and hypertension." | 3.66 | Labetalol in the treatment of hypertensive renal patients. ( Craswell, PW; De Voss, K; Williams, JG, 1978) |
| " Similarly, the absolute bioavailability of an oral dose of 200 mg of labetalol was 0." | 2.67 | Bioavailability of labetalol in patients with end-stage renal disease. ( Awni, WM; Halstenson, CE; Luke, DR; Matzke, GR; Opsahl, JA, 1992) |
| " Values of Cmax, Tmax, half-life or renal elimination did not significantly change with decreased renal function." | 1.28 | The pharmacokinetics of dilevalol in renal impairment. ( Donohue, J; Doyle, GD; Kelly, JG; Laher, MS, 1990) |
| "3 Labetalol has a relatively large apparent volume of distribution (3." | 1.26 | Elimination kinetics of labetalol in severe renal failure. ( Bailey, RR; Ferry, DG; Wood, AJ, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (46.15) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, H | 1 |
| Sim, JJ | 1 |
| Shi, J | 1 |
| Shaw, SF | 1 |
| Lee, MS | 1 |
| Neyer, JR | 1 |
| Kovesdy, CP | 1 |
| Kalantar-Zadeh, K | 1 |
| Jacobsen, SJ | 1 |
| Chhabra, R | 1 |
| Magee, C | 1 |
| Merino, JL | 1 |
| Espejo, B | 1 |
| Ferreiro, P | 1 |
| Bueno, B | 1 |
| Paraíso, V | 1 |
| Kujal, P | 1 |
| Chábová, VČ | 1 |
| Vernerová, Z | 1 |
| Walkowska, A | 1 |
| Kompanowska-Jezierska, E | 1 |
| Sadowski, J | 1 |
| Vaňourková, Z | 1 |
| Husková, Z | 1 |
| Opočenský, M | 1 |
| Skaroupková, P | 1 |
| Schejbalová, S | 1 |
| Kramer, HJ | 1 |
| Rakušan, D | 1 |
| Malý, J | 1 |
| Netuka, I | 1 |
| Vaněčková, I | 1 |
| Kopkan, L | 1 |
| Cervenka, L | 1 |
| Prichard, BN | 1 |
| Lifshits, NL | 1 |
| Ermolenko, VM | 1 |
| Rozhdestvenskaia, TM | 1 |
| Tatsievskiĭ, VA | 1 |
| Panasiuk, VV | 1 |
| El Matri, A | 1 |
| Kechrid, C | 1 |
| Larabi, M | 1 |
| Belkahia, C | 1 |
| Ben Ayed, H | 1 |
| Wood, AJ | 1 |
| Ferry, DG | 1 |
| Bailey, RR | 1 |
| Williams, JG | 1 |
| De Voss, K | 1 |
| Craswell, PW | 1 |
| Luke, DR | 2 |
| Awni, WM | 2 |
| Halstenson, CE | 1 |
| Opsahl, JA | 1 |
| Matzke, GR | 2 |
| Kelly, JG | 1 |
| Laher, MS | 1 |
| Donohue, J | 1 |
| Doyle, GD | 1 |
| Arthur, S | 1 |
| Greenberg, A | 1 |
| Clarkson, JT | 1 |
1 review available for labetalol and Kidney Failure, Chronic
| Article | Year |
|---|---|
Combined alpha- and beta-receptor inhibition in the treatment of hypertension.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthesia; Antihyp | 1984 |
1 trial available for labetalol and Kidney Failure, Chronic
| Article | Year |
|---|---|
Bioavailability of labetalol in patients with end-stage renal disease.
Topics: Administration, Oral; Adult; Biological Availability; Blood Pressure; Female; Humans; Injections, In | 1992 |
11 other studies available for labetalol and Kidney Failure, Chronic
| Article | Year |
|---|---|
β-Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atenolol; Bisoprolol; Carvedilol; Cause of Dea | 2021 |
A case of posterior reversible encephalopathy syndrome.
Topics: Aged; Antihypertensive Agents; Female; Humans; Hypertension; Kidney Failure, Chronic; Labetalol; Pos | 2016 |
[Pregnancy and advanced chronic kidney disease].
Topics: Ductus Arteriosus, Patent; Epilepsy; Female; Fetal Growth Retardation; Humans; Hyaline Membrane Dise | 2010 |
Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2010 |
[Labetalol and guanfacine in the treatment of arterial hypertension in patients with chronic renal failure].
Topics: Adolescent; Adult; Antihypertensive Agents; Drug Therapy, Combination; Ethanolamines; Female; Guanfa | 1984 |
[Combined captopril and labetalol treatment of malignant arterial hypertension (author's transl)].
Topics: Adult; Captopril; Drug Synergism; Drug Therapy, Combination; Ethanolamines; Female; Heart Failure; H | 1981 |
Elimination kinetics of labetalol in severe renal failure.
Topics: Adult; Aged; Blood Urea Nitrogen; Creatinine; Ethanolamines; Female; Glomerular Filtration Rate; Hal | 1982 |
Labetalol in the treatment of hypertensive renal patients.
Topics: Adrenergic beta-Antagonists; Adult; Drug Therapy, Combination; Ethanolamines; Female; Humans; Hydral | 1978 |
The pharmacokinetics of dilevalol in renal impairment.
Topics: Administration, Oral; Adult; Aged; Female; Glomerular Filtration Rate; Half-Life; Humans; Hypertensi | 1990 |
Hyperkalemia associated with intravenous labetalol therapy for acute hypertension in renal transplant recipients.
Topics: Adult; Humans; Hyperkalemia; Hypertension; Infusions, Intravenous; Kidney Failure, Chronic; Kidney T | 1990 |
Improved liquid-chromatographic assay of labetalol in plasma.
Topics: Chromatography, High Pressure Liquid; Humans; Kidney Failure, Chronic; Kinetics; Labetalol; Specimen | 1987 |